Drugs in the Testosterone Class Action Lawsuit

Drugs in the Testosterone Class Action Lawsuit

If you or a loved one has been harmed due to low testosterone (LOW T) treatment, you can potentially be eligible for monetary compensation. In the past, there have been very few decisions from courts regarding compensation regarding the injuries caused by low testosterone. However, this is no longer the case as some doctors are now acknowledging the side-effects of treating with testosterone in the form of injections. There can be large sums of money awarded in claims and medical settlements from such claims.

For those who suffer ill health due to exposing themselves to testosterone products, they are not alone. The Food and Drug Administration (FDA) estimates that more than two million men in the United States have been negatively impacted by exposing themselves to drugs and other pharmaceutical products containing testosterone. Such victims include athletes competing in high-level athletic events, bodybuilders using dangerous substances to build muscle mass, and men who produce surplus quantities of testosterone in order to promote sexual activity. It is important that if you have been injured as a result of such negligence, that you contact an experienced attorney experienced in litigating these types of cases.

The Federal Trade Commission has brought several testosterone class action lawsuit cases against various companies involved in the production, distribution, and sale of prescription and over-the-counter drugs containing testosterone. The Federal Trade Commission has alleged that Merck, Ortho-ometrics Inc., Cipro, Inc., Allianz Worldwide, Lupron Inc., and Jansport Corporation engaged in a conspiracy to introduce controlled substances into the market for purposes of unfair competition. The charges in the complaint further state that the companies failed to warn the public about the potential dangers of their drugs, and did not take reasonable steps to prevent the accidental ingestion of controlled substances by consumers. Additionally, the complaint states that the companies failed to make proper disclosure of the extent of the risks inherent in taking certain kinds of testosterone replacement therapies. Such actions, the complaint continues, violate the federal Lanham Act and the Due Process and Fair Trading Clauses applicable to the states.

As the FDA and the courts have ruled, as well, these kinds of testosterone therapies are not necessarily dangerous. They have been used successfully for decades by thousands of men with various kinds of ailments, including those with blocked arteries, enlarged heart arteries, sleep apnea, enlarged spleen, enlarged liver, prostate problems, and growth deficiencies. Further, studies have shown that, over time, the use of these kinds of medications can help to prolong life, lower cholesterol levels, lower blood pressure, and increase muscle strength and stamina. Further, many of these medications have been approved by the FDA for treating conditions like low testosterone concentrations, and hormone-related acne, high blood pressure, enlarged prostate, and some forms of depression. There have also been some studies conducted by major hospitals wherein patients who took these medications were found to have a decreased chance of suffering from depression or heart attacks, a decrease in their chance of having multiple sclerosis, and a decrease in their chances of developing aggressive behaviors like obesity and substance abuse.

One of the drugs involved in this lawsuit is Geodon, which is a drug used to treat congenital heart defects in newborns. It is manufactured by AstraZeneca and is scheduled to be approved by the FDA later this year. Despite the positive results of this medication in some trials and despite the fact that there are no serious side effects being reported by the people taking it, AstraZeneca has filed a class-action lawsuit against GlaxoSmithKline and its subsidiary Nupretin. These companies, through their marketing campaigns and their endorsements by medical bodies and physicians around the globe, have “misled the American consumer about the risks associated with the use of Delatestryl,” the suit states.

Other drugs involved in the lawsuit are Optin, Acelite, TriCe, Bensodiazepine, Cortezine, and Librium. The class-action lawsuit was initiated on behalf of the plaintiff by the law firm of Williams Kherkher in Palm Beach, Florida. Class-action injury litigation is a method of bringing about compensation for victims of defective products with claims being resolved through court judgments and mandatory arbitration. If you are a victim of defective drugs and feel that you deserve compensation for your injuries, contact a personal injury lawyer today who specializes in these cases.

Laws